Lupus Science & MedicineImmunologyPeer-reviewed journal article
Inflammation in Areas of Fibrosis Precedes Loss of Kidney Function in Lupus Nephritis
Silvia MalvicaiD, Paride FenaroliiD, Chen‐Yu LeeiD, Sarah Louis, Alessandra Ida CeliaiD, Serena Maria BagnascoiD, Xiaoping YangiD, Daniel Salvetti, Jeffrey B. HodginiD, Michael H BelmontiD, Peter IzmirlyiD, Jill P. BuyoniD, Laurence S. MagderiD, Michelle PetriiD, The Accelerating Medicines Partnership: RA/SLE Network, Avi Z. RosenbergiD, Andrea FavaiD
Abstract
BackgroundInterstitial fibrosis in lupus nephritis (LN) is often infiltrated by immune cells but typically regarded as nonspecific "scar reaction." This study aimed to investigate the relationship between inflammatory fibrosis and kidney disease progression in LN. MethodsInterstitial fibrosis and tubular atrophy (IFTA) were scored in 124 LN kidney biopsies. Inflammation in areas of IFTA (i-IFTA) was graded 0-3 according to the Banff Classification of Allograft Pathology. Significant glomerular filtration rate (GFR) loss was defined as a decline of >15 ml/min at 3 years from biopsy. Immune cell phenotype was defined by serial immunohistochemistry (13-plex). ResultsIFTA was observed in 88/124 (71%) biopsies, and i-IFTA was identified in 76/88 (86%) cases. The distribution of i-IFTA grades was heterogenous across all IFTA grades. In patients with moderate-to-severe IFTA (>25%), the degree of i-IFTA was associated with a higher risk of significant GFR loss: 0/2 (0%), 1/3 (33%), 3/4 (75%), and 7/9 (78%) for i-IFTA grades 0, 1, 2, and 3, respectively (p = 0.028). Multiplexed histology revealed that i-IFTA was mostly composed of CD163+ macrophages and CD4 T cells, followed by CD8 T cells and granulocytes. ConclusionI-IFTA is frequently observed in LN and is dominated by macrophages and T cells. For patients with baseline IFTA >25%, the degree of i-IFTA emerged as a predictor of GFR loss. These data support the routine scoring of i-IFTA in LN due to its prognostic implications and nominate i-IFTA as a potential therapeutic target. LAY SUMMARYScar tissue often contains immune cells, but we still do not fully understand their role. In lupus nephritis (LN), this is typically dismissed as "nonspecific inflammation". However, our study analyzed kidney biopsies from 124 people with LN and found that inflammation in scarred areas may predict future kidney function loss. Specifically, we identified a type of immune cell, CD163+ macrophages, that may contribute to scarring and kidney damage. Our findings suggest that routinely assessing inflammation in scarred areas could help predict kidney health in LN patients and highlight a possible new target for therapies to prevent kidney damage.
- Citations
- 6
- FWCI
- 3.95
- Field percentile
- top 6%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Rethinking the Benign Nature of Class II Lupus Nephritis
Jasmine Shwetar, Andrea Fava, … Kelly V. Ruggles·bioRxiv·Sep 18, 2026
- Spatially Distinct Macrophage Subsets Drive Myofibroblast Heterogeneity and Maladaptive Fibrosis in Lupus Nephritis
Chirag Raparia, Paul Hoover, … Anne Davidson·Annals of the Rheumatic DiseasesPeer-reviewed·Aug 1, 2026
- Deep profiling of lupus nephritis kidneys reveals dynamic changes in myeloid cells associated with disease progression
Paul Hoover, Thomas Eisenhaure, … Arnon Arazi·Annals of the Rheumatic DiseasesPeer-reviewed·Apr 28, 2026
- Insights from Comparison of the Renal and Skin Single Cell Transcriptomes in Lupus Nephritis
E. Der, H. Suryawanshi, … C. Putterman·bioRxiv·Dec 31, 2019
- CD8 T lymphocytes infiltrate the kidneys and correlate with disease progression in B6.NZMSle1/Sle2/Sle3 lupus mice
Pauline Montigny, Selda Aydın, … Pierre G. Coulie·bioRxiv·Nov 3, 2025
- Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis
A. Horisberger, A. Griffith, … Accelerating Medicines Pa·bioRxiv·Jan 14, 2024